(Q22241424)

6 February 2023

7

Wolfgang Oertel

Wolfgang

Oertel

1 reference

6 February 2023

1

Richard Dodel

Richard

Dodel

1 reference

6 February 2023

3

Carmen Noelker

Carmen

Noelker

1 reference

6 February 2023

6

Michael Bacher

Michael

Bacher

1 reference

6 February 2023

Refik Pul

4

Refik

Pul

1 reference

1048571828

6 February 2023

Yansheng Du

series ordinal

5

author given names

Yansheng

author last names

Du

1 reference

1048571828

Reduced levels of amyloid beta-peptide antibody in Alzheimer disease

6 February 2023

language of work or name

English

0 references

publication date

March 2010

0 references

published in

Drugs

0 references

volume

70

0 references

issue

5

0 references

page(s)

513-528

0 references

cites work

1 reference

https://api.crossref.org/works/10.2165%2F11533070-000000000-00000

Serum anti-amyloid-beta antibodies and Alzheimer's disease in elderly Korean patients

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11533070-000000000-00000

Mechanisms of action of IVIg and therapeutic considerations in the treatment of acute and chronic demyelinating neuropathies

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11533070-000000000-00000

Complications of intravenous immune globulin treatment in neurologic disease

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11533070-000000000-00000

Evaluation of the safety and immunogenicity of synthetic A 42 (AN1792) in patients with AD

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11533070-000000000-00000

Anti-inflammatory activity of IVIG mediated through the inhibitory Fc receptor

21 January 2018

1 reference

12 December 2020

Passive amyloid immunotherapy clears amyloid and transiently activates microglia in a transgenic mouse model of amyloid deposition.

1 reference

12 December 2020

EFNS guidelines for the use of intravenous immunoglobulin in treatment of neurological diseases: EFNS task force on the use of intravenous immunoglobulin in treatment of neurological diseases

1 reference

12 December 2020

Therapy with Intravenous Immunoglobulins: Complications and Side-Effects

1 reference

12 December 2020

Immunotherapy and naturally occurring autoantibodies in neurodegenerative disorders

1 reference

12 December 2020

Anti-Inflammatory Activity of Immunoglobulin G Resulting from Fc Sialylation

1 reference

12 December 2020

Autoantibodies to neurofibrillary tangles and brain tissue in Alzheimer's disease. Establishment of Epstein-Barr virus-transformed antibody-producing cell lines

1 reference

12 December 2020

Basic principles of intravenous immunoglobulin (IVIg) treatment

1 reference

12 December 2020

Pharmacy considerations for the use of IGIV therapy

1 reference

12 December 2020

Nasal vaccination with a proteosome-based adjuvant and glatiramer acetate clears beta-amyloid in a mouse model of Alzheimer disease

1 reference

12 December 2020

Amyloid-beta immunization effectively reduces amyloid deposition in FcRgamma-/- knock-out mice

1 reference

12 December 2020

Identification of a receptor required for the anti-inflammatory activity of IVIG.

1 reference

12 December 2020

Responding to the immunoglobulin shortage: a case study

1 reference

12 December 2020

Patients with Alzheimer disease have lower levels of serum anti-amyloid peptide antibodies than healthy elderly individuals

1 reference

12 December 2020

Identification of autoantibody against beta-amyloid peptide in the serum of elderly.

1 reference

12 December 2020

1 reference

12 December 2020

Human anti-beta-amyloid antibodies block beta-amyloid fibril formation and prevent beta-amyloid-induced neurotoxicity

1 reference

12 December 2020

Intravenous immunoglobulins containing antibodies against beta-amyloid for the treatment of Alzheimer's disease

1 reference

12 December 2020

Autoantibodies to amyloid beta-peptide (Abeta) are increased in Alzheimer's disease patients and Abeta antibodies can enhance Abeta neurotoxicity: implications for disease pathogenesis and vaccine development

1 reference

12 December 2020

The effects of intravenous immune globulin on complement-dependent immune damage of cells and tissues

1 reference

12 December 2020

Shortage of human intravenous immunoglobulin—reasons and possible solutions

1 reference

12 December 2020

Safety of intravenous immunoglobulin (IVIG) therapy

1 reference

12 December 2020

Cerebral hemorrhage after passive anti-Abeta immunotherapy.

1 reference

12 December 2020

IGIV: contents, properties, and methods of industrial production--evolving closer to a more physiologic product

1 reference

12 December 2020

Immunomodulation of autoimmune and inflammatory diseases with intravenous immune globulin

1 reference

12 December 2020

Autoimmune responses to amyloid structures of Abeta(25-35) peptide and human lysozyme in the serum of patients with progressive Alzheimer's disease

1 reference

12 December 2020

Imaging of amyloid-beta deposits in brains of living mice permits direct observation of clearance of plaques with immunotherapy.

1 reference

12 December 2020

Amyloid-beta protein dimers isolated directly from Alzheimer's brains impair synaptic plasticity and memory

1 reference

12 December 2020

Safety of IGIV therapy and infusion-related adverse events

1 reference

12 December 2020

A fibril-specific, conformation-dependent antibody recognizes a subset of Abeta plaques in Alzheimer disease, Down syndrome and Tg2576 transgenic mouse brain

1 reference

12 December 2020

Side effects of intravenous immunoglobulins in neurological autoimmune disorders--a prospective study

1 reference

12 December 2020

F(ab)'2-mediated neutralization of C3a and C5a anaphylatoxins: a novel effector function of immunoglobulins

1 reference

12 December 2020

In vivo modulation of cytokine synthesis by intravenous immunoglobulin

1 reference

12 December 2020

Autoantibodies against beta-amyloid are common in Alzheimer's disease and help control plaque burden.

1 reference

12 December 2020

Peripherally administered antibodies against amyloid beta-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease

1 reference

12 December 2020

Intravenous immunoglobulin in neurological disorders: a mechanistic perspective

1 reference

12 December 2020

Anti-inflammatory actions of intravenous immunoglobulin

1 reference

12 December 2020

Adverse events associated with intravenous immunoglobulin therapy

1 reference

12 December 2020

Human antibodies reactive with beta-amyloid protein in Alzheimer's disease

1 reference

12 December 2020

Therapeutic efficacy of intravenous immunoglobulin preparations depends on the immunoglobulin G dimers: studies in experimental immune thrombocytopenia

1 reference

12 December 2020

Intravenous immunoglobulin (IVIG)-mediated neutralisation of C5a: a direct mechanism of IVIG in the maintenance of a high Fc gammaRIIB to Fc gammaRIII expression ratio on macrophages

1 reference

12 December 2020

Appropriate uses of human immunoglobulin in clinical practice: memorandum from an IUIS/WHO meeting

1 reference

12 December 2020

18-Month study of intravenous immunoglobulin for treatment of mild Alzheimer disease.

1 reference

12 December 2020

Reversal of immune thrombocytopenia in mice by cross-linking human immunoglobulin G with a high-affinity monoclonal antibody

1 reference

12 December 2020

APP transgenic mice: the effect of active and passive immunotherapy in cognitive tasks

1 reference

12 December 2020

IV immunoglobulin is associated with a reduced risk of Alzheimer disease and related disorders

1 reference

12 December 2020

Immune response to Abeta-peptides in peripheral blood from patients with Alzheimer's disease and control subjects

1 reference

12 December 2020

Intravenous immunoglobulin enhances the clearance of fibrillar amyloid-beta peptide

1 reference

12 December 2020

Autoantibodies to redox-modified oligomeric Abeta are attenuated in the plasma of Alzheimer's disease patients.

1 reference

12 December 2020

Antibodies against beta-amyloid slow cognitive decline in Alzheimer's disease

1 reference

12 December 2020

Antibody-mediated immunotherapy for Alzheimer's disease

1 reference

12 December 2020

Decreased serum amyloid beta(1-42) autoantibody levels in Alzheimer's disease, determined by a newly developed immuno-precipitation assay with radiolabeled amyloid beta(1-42) peptide.

1 reference

12 December 2020

Active and passive immunotherapy for neurodegenerative disorders

1 reference

12 December 2020

High-dose intravenous immunoglobulin treatment activates complement in vivo

1 reference

12 December 2020

Comparison of intravenous immunoglobulin preparations on microglial function in vitro: more potent immunomodulatory capacity of an IgM/IgA-enriched preparation.

1 reference

12 December 2020

The MHC class I-like Fc receptor promotes humorally mediated autoimmune disease

1 reference

12 December 2020

Colony-stimulating factor-1-dependent macrophages are responsible for IVIG protection in antibody-induced autoimmune disease

1 reference

12 December 2020

Detection of circulating antibodies against tau protein in its unphosphorylated and in its neurofibrillary tangles-related phosphorylated state in Alzheimer's disease and healthy subjects.

1 reference

12 December 2020

Structure and function of amyloid in Alzheimer's disease

1 reference

12 December 2020

Autoantibodies to alpha-synuclein in inherited Parkinson's disease.

1 reference

12 December 2020

sHLA-I contaminating molecules as novel mechanism of ex vivo/in vitro transcriptional and posttranscriptional modulation of transforming growth factor-beta in CD8+ T lymphocytes and neutrophils after intravenous immunoglobulin treatment.

1 reference

12 December 2020

High doses of immunoglobulin G attenuate immune aggregate-mediated complement activation by enhancing physiologic cleavage of C3b in C3bn-IgG complexes

1 reference

12 December 2020

Inhibitory effect of pooled human immunoglobulin on cytokine production in peripheral blood mononuclear cells.

1 reference

12 December 2020

Regulation of Fcgamma receptors and immunoglobulin G-mediated phagocytosis in mouse microglia

1 reference

12 December 2020

Reduced levels of amyloid-beta-binding proteins in cerebrospinal fluid from Alzheimer's disease patients.

1 reference

12 December 2020

Advances in the understanding of the mechanism of action of IVIg

1 reference

12 December 2020

Disease-modifying therapies for Alzheimer disease: challenges to early intervention

1 reference

12 December 2020

Human plasma contains cross-reactive Abeta conformer-specific IgG antibodies

1 reference

12 December 2020

Internalized antibodies to the Abeta domain of APP reduce neuronal Abeta and protect against synaptic alterations.

1 reference

12 December 2020

Intravenous immunoglobulin ameliorates ITP via activating Fc gamma receptors on dendritic cells

1 reference

12 December 2020

Structural principles of tau and the paired helical filaments of Alzheimer's disease

1 reference

12 December 2020

Assessment of the bioactivity of antibodies against beta-amyloid peptide in vitro and in vivo.

1 reference

12 December 2020

Autoantibodies to amyloid-beta and Alzheimer's disease.

1 reference

12 December 2020

Intravenous immunoglobulins and transforming growth factor beta.

1 reference

12 December 2020

Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse

1 reference

12 December 2020

Clinical effects of Abeta immunization (AN1792) in patients with AD in an interrupted trial.

1 reference

12 December 2020

FcgammaRIII-dependent inhibition of interferon-gamma responses mediates suppressive effects of intravenous immune globulin

1 reference

12 December 2020

Long-term effects of Abeta42 immunisation in Alzheimer's disease: follow-up of a randomised, placebo-controlled phase I trial

1 reference

12 December 2020

A structural model for Alzheimer's beta -amyloid fibrils based on experimental constraints from solid state NMR

1 reference

12 December 2020

Amyloid-beta immunotherapy for Alzheimer's disease: the end of the beginning

1 reference

12 December 2020

Increased blood plasma concentrations of TGF-beta1 and TGF-beta2 after treatment with intravenous immunoglobulins in childhood autoimmune diseases

1 reference

12 December 2020

Has the amyloid cascade hypothesis for Alzheimer's disease been proved?

1 reference

12 December 2020

Drug Insight: the use of intravenous immunoglobulin in neurology--therapeutic considerations and practical issues

1 reference

12 December 2020

Comparison of intravenous immunoglobulins for naturally occurring autoantibodies against amyloid-beta

1 reference

12 December 2020

Differences between IGIV products: impact on clinical outcome

1 reference

12 December 2020

Neuropathology of human Alzheimer disease after immunization with amyloid-beta peptide: a case report.

1 reference

12 December 2020

A beta peptide vaccination prevents memory loss in an animal model of Alzheimer's disease

1 reference

12 December 2020

Autoantibody-catalyzed hydrolysis of amyloid beta peptide

1 reference

12 December 2020

Immunoglobulins for intravenous use inhibit TNF alpha cytotoxicity in vitro

1 reference

12 December 2020

Peripheral anti-A beta antibody alters CNS and plasma A beta clearance and decreases brain A beta burden in a mouse model of Alzheimer's disease

1 reference

12 December 2020

Immunization reverses memory deficits without reducing brain Abeta burden in Alzheimer's disease model.

1 reference

12 December 2020

Increased incidence of anti-beta-amyloid autoantibodies secreted by Epstein-Barr virus transformed B cell lines from patients with Alzheimer's disease

1 reference

12 December 2020

Human monoclonal antibodies against amyloid-beta from healthy adults

1 reference

12 December 2020

Low avidity and level of serum anti-Abeta antibodies in Alzheimer disease.

1 reference

12 December 2020

Human antibodies against amyloid beta peptide: a potential treatment for Alzheimer's disease.

1 reference

12 December 2020

Conformation-sensitive antibodies against alzheimer amyloid-beta by immunization with a thioredoxin-constrained B-cell epitope peptide

1 reference

12 December 2020

Autoimmunity in Alzheimer's disease: increased levels of circulating IgGs binding Abeta and RAGE peptides

1 reference

12 December 2020

Fcgamma receptors as regulators of immune responses

1 reference

12 December 2020

10.2165/11533070-000000000-00000

Identifiers

DOI

0 references